Share the post "Anuh Pharma : Q4 2024 Financial Quarterly Report : YoY Sales Up 4.18 %, QoQ Down 4.77 %"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 4.18 % in the past year, decrease in net sales/revenue by -4.77 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 173.79 %. Marginal decrease of -22.74% in other income during this quarter.
- Profit over the Year and quarter: Significant improvement in profitability for Anuh Pharma Ltd.,. Notable increase of 59.6 % in net profit Year to Year, Anuh Pharma Ltd.,’s profitability dropped by -19.65 % Quarter to Quarter.
- EPS over the Year and quarter: EPS increased by 59.38 % Year to Year. EPS decreased by -19.69 % in previous quarter. Analysis needed for shareholder value.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 157.31 Cr | Rs. 172.101 Cr | Rs. 163.891 Cr | -4.77 % | + 4.18 % |
Expenses | Rs. 143.08 Cr | Rs. 148.11 Cr | Rs. 144.67 Cr | -2.32 % | + 1.11 % |
Operating Profit | Rs. 14.23 Cr | Rs. 23.99 Cr | Rs. 19.22 Cr | -19.88 % | + 35.07 % |
OPM % | 9.05 % | 13.94 % | 11.73 % | -2.21 % | + 2.68 % |
Other Income | Rs. 1.03 Cr | Rs. 3.65 Cr | Rs. 2.82 Cr | -22.74 % | + 173.79 % |
Interest | Rs. 0.02 Cr | Rs. 0.14 Cr | Rs. 0.1 Cr | -28.57 % | + 400 % |
Depreciation | Rs. 2.41 Cr | Rs. 2.2 Cr | Rs. 2.23 Cr | + 1.36 % | -7.47 % |
Profit before tax | Rs. 12.83 Cr | Rs. 25.3 Cr | Rs. 19.71 Cr | -22.09 % | + 53.62 % |
Tax % | 25.05 % | 24.47 % | 22.11 % | -2.36 % | -2.94 % |
Net Profit | Rs. 9.62 Cr | Rs. 19.11 Cr | Rs. 15.36 Cr | -19.62 % | + 59.67 % |
EPS in Rs | Rs. 1.92 | Rs. 3.81 | Rs. 3.06 | -19.69 % | + 59.38 % |
Today, we’re looking at Anuh Pharma Ltd.,’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 4.18 %. However, it did see a marginal slip of -4.77 % from the previous quarter. Expenses decreased slightly by -2.32 % quarter-on-quarter, aligning with the annual rise of 1.11 %. Operating profit, while up 35.07 % compared to last year, faced a quarter-on-quarter dip of -19.88 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.68 %, but a shrinkage of -2.21 % sequentially. Other income fell by -22.74 % compared to the last quarter, despite an annual growth of 173.79 %. Interest expenses dropped significantly by -28.57 % from the previous quarter, yet the year-over-year increase remains at a moderate 400 %. Depreciation costs climbed by 1.36 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -7.47 %. Profit before tax grew annually by 53.62 % but saw a reduction from the preceding quarter by -22.09 %.
Tax expenses as a percentage of profits decreased slightly by -2.94 % compared to last year, with a more notable quarter-on-quarter decrease of -2.36 %. Net profit rose by 59.67 % year-on-year but witnessed a -19.62 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 59.38 % but a quarterly fall of -19.69 %. In summary, Anuh Pharma Ltd.,’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 157.31 Cr | Rs. 172.101 Cr | Rs. 163.891 Cr | -4.77 % | + 4.18 % |
Expenses | Rs. 143.08 Cr | Rs. 148.11 Cr | Rs. 144.67 Cr | -2.32 % | + 1.11 % |
Operating Profit | Rs. 14.23 Cr | Rs. 23.99 Cr | Rs. 19.22 Cr | -19.88 % | + 35.07 % |
Net Profit | Rs. 9.62 Cr | Rs. 19.11 Cr | Rs. 15.36 Cr | -19.62 % | + 59.67 % |
EPS in Rs | Rs. 1.92 | Rs. 3.81 | Rs. 3.06 | -19.69 % | + 59.38 % |
In reviewing Anuh Pharma Ltd.,’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 4.18 % year-on-year growth, although there was a slight dip of -4.77 % from the previous quarter. Expenses rose by 1.11 % compared to the previous year, with a decrease of -2.32 % quarter-on-quarter. Operating Profit surged by 35.07 % annually, and saw a -19.88 % decrease from the last quarter.
Net Profit showed yearly increase of 59.67 %, and experienced a -19.62 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 59.38 % annually, however dipped by -19.69 % compared to the last quarter. In essence, while Anuh Pharma Ltd., exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
32
3-Year Profit
19
5-Year Profit
12
10-Year Profit
226
Current Price
1,135
Market Cap
The financial outlook for the company under BSE code 506260 reveals a significant five-year profit of 19 percents. This marks a notable increase to 32 percents over the last three years, indicating a strong upward trend in the company's financial health during this period. However, it's important to note that recent challenges have impacted the company's performance, leading to a trailing twelve-month loss of 42 percents. This sharp decline in profitability is particularly concerning, as the company has also reported no sales across any analyzed timeframe, suggesting a highly unconventional and perhaps risky operational approach. The company's stock prices mirror this financial volatility, with the stock trading at 24 percents over the past five years but experiencing a dramatic drop to 60 percents within the last year. Over a decade, the stock price was at 15 percents, reflecting long-term concerns regarding the company's stability and future outlook. Such performance poses questions about the sustainability of the business and whether it can rebound from these recent setbacks.
The company has a market capitalization of ₹1,135 crore and is currently trading at a stock price of ₹226. Over time, the stock has fluctuated between the historical highs and lows of ₹265 / 101, reflecting the market's volatility. With a Price-to-Earnings (P/E) ratio of 18.9, the stock appears highly valued, indicating that investors are willing to pay a premium for its earnings potential. The company's book value per share stands at ₹58.1, showcasing the underlying asset value. Additionally, the dividend yield is 1.10%, suggesting that the company offers shareholders a moderate return on their investment in the form of dividends. The Return on Capital Employed (ROCE) is 29.4%, indicating the efficiency with which the company generates profit from its capital. Meanwhile, the Return on Equity (ROE) is 22.6%, highlighting the profitability relative to shareholder equity. Despite these figures, the company maintains a very low debt-to-equity ratio of 0.01, signaling minimal leverage. It also reports a net cash flow of ₹5.27 crore, reflecting the company's ability to generate cash. The Piotroski score is 8.00, a measure of the company's financial strength, while the Graham Number estimates the intrinsic value of the stock at ₹125. The Price-to-Book (P/B) ratio of 3.90 further suggests that the stock is trading at a premium relative to its book value, potentially reflecting positive market sentiment or expectations of future growth.